Best Small Cell Vs Non Small Cell Lung Cancer Podcasts (2025)

1
S13 Ep37: Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD 5:04

Play Pause

1h ago5:04

5:04

In today’s episode, we had the pleasure of speaking with Connie Lai, MD, a medical oncology resident at Queen Elizabeth Hospital in Hong Kong, about a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer (mCRC).By OncLive® On Air

1
S13 Ep36: CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD 15:17

3d ago15:17

15:17

In today’s OncClub episode, we had the pleasure of speaking with Branden Moriarity, PhD; and Beau Webber, PhD, about a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers. Dr Moriarity is an associate professor in the Division of Pediatric Hematology/Onc…

1
JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma 24:50

4d ago24:50

24:50

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: We…

1
S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD 9:59

7d ago9:59

9:59

In today’s episode, we spoke with Joshua K. Sabari, MD, about the use of telisotuzumab vedotin-tllv (Emrelis) in patients with c-MET–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Sabari is an assistant professor in the Department of Medicine at the New York University Grossman School of Medicine; as wel…

1
S13 Ep34: Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD 45:46

8d ago45:46

45:46

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will welcome a…

1
S13 Ep33: Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC 21:40

10d ago21:40

21:40

In our exclusive interview, Drs Leleu and Faiman discussed the unique methods and design of IRAKLIA, key efficacy and safety findings from this trial, and the benefits of using on-body delivery systems to deliver effective therapies to patients in more convenient and patient-centered ways.By OncLive® On Air

1
S13 Ep32: European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD 11:54

14d ago11:54

11:54

In today’s episode, we had the opportunity to speak with Arndt Vogel, MD, about the European Commission’s (EC's) July 2025 marketing authorization of zanidatamab-hrii (Ziihera) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. Dr Vogel is a faculty member at…

1
S13 Ep31: IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD 28:45

15d ago28:45

28:45

In today’s episode, we had the pleasure of speaking with Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD, about a study they conducted investigating the use of immunohistochemistry (IHC) as a biomarker for early TP53 mutation identification in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Gerber is a member …

1
S13 Ep30: Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ 18:29

16d ago18:29

18:29

In today’s episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast s…

1
S13 Ep29: FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP 11:14

17d ago11:14

11:14

In today’s episode, supported by Thermo Fisher Scientific, we had the pleasure of speaking with Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP, about the FDA approval of the Oncomine DX Express Test for use as a companion diagnostic for sunvozertinib (Zegfrovy) in EGFR exon 20 insertion mutation–positive non–small cell lung cancer…

1
S13 Ep28: Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD 11:20

21d ago11:20

11:20

In today’s episode, supported by Coherus BioSciences, we had the pleasure of speaking with Justine Bruce, MD, about the ongoing evolution of nasopharyngeal carcinoma management. Dr Bruce is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well a…

1
S13 Ep26: ASCO 2025 Plenary — MATTERHORN 12:14

24d ago12:14

12:14

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
S13 Ep25: FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS 16:41

28d ago16:41

16:41

In today’s episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Da…

1
S13 Ep24: Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD 6:39

29d ago6:39

6:39

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line sett…

51
S13 Ep23: IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD 7:32

1M ago7:32

7:32

In today’s episode, supported by Immatics, we had the pleasure of speaking with Justin Moser, MD, about the ongoing phase 3 SUPRAME trial investigating the PRAME-directed T-cell receptor T-cell therapy IMA203 vs treatment of physician's choice in patients with previously treated, unresectable or metastatic cutaneous melanoma. Dr Moser is an associa…

1
JCO Article Insights: Pooled Taletrectinib Efficacy and Safety 15:02

1M ago15:02

15:02

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this e…

51
S13 Ep22: BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD 9:27

1M ago9:27

9:27

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, a gastrointestinal oncologist at Allegheny Health Network in Pittsburgh, Pennsylvania, to discuss treatment personalization in metastatic colorectal cancer (mCRC), w…

51
S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD 6:18

1M ago6:18

6:18

In today’s episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in pretreated patients with HER2-mutated non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Divisi…

1
S13 Ep20: ASCO 2025 Plenary: SERENA-6 12:33

1M ago12:33

12:33

In this episode, OncLive On Air® partnered with Two Onc Docs to bring discussion of data from the phase 3 SERENA-6 trial (NCT04964934), which were presented at the 2025 ASCO Annual Meeting. SERENA-6 evaluated switching to camizestrant plus a CDK4/6 inhibitor vs continuing with a standard-of-care aromatase inhibitor plus a CDK4/6 inhibitor in the fr…

1
S13 Ep19: Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD 15:55

1M ago15:55

15:55

In today’s episode, supported by Coherus BioSciences, we had the pleasure of speaking with Michael Dennis, MD, about recent updates to the nasopharyngeal carcinoma treatment paradigm. Dr Dennis is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School, both in Boston, Massachusetts. In our exclus…

1
S13 Ep18: Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD 19:58

1M ago19:58

19:58

In today’s episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is t…

1
S13 Ep17: 42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER 26:40

1M ago26:40

26:40

Episode Description In this podcast, expert Hope Rugo, MD, discusses her approach to treating patients with hormone receptor–positive/HER2-negative breast cancer from the early-stage to metastatic disease. Consideration of these complex clinical scenarios taken from tumor board discussions at the 42nd Annual Miami Breast Cancer Conference® highligh…

1
S13 Ep16: Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS 11:10

1M ago11:10

11:10

In today’s episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Ketter…

1
S13 Ep15: The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH 11:25

2M ago11:25

11:25

In our exclusive interview, Dr Morgans detailed the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide (Nubeqa) for this population. She discussed treatment considerations for determining whether to give docetaxel along with darolutamide; other factors to remember with AR inhibition; and the…

1
S13 Ep14: Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD 11:04

2M ago11:04

11:04

In today’s episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas M…

1
S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD 14:41

2M ago14:41

14:41

In today’s episode, we spoke with Paolo Tarantino, MD, about key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual MeetingBy OncLive® On Air

1
S13 Ep12: Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD 9:26

2M ago9:26

9:26

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematol…

1
S13 Ep11: Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM 9:48

2M ago9:48

9:48

In today’s episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Depar…

1
S13 Ep10: Updates and Innovations in Non-Opioid Pain Management Strategies for Breast Cancer Patients Post-Surgical Intervention 1:32:30

2M ago1:32:30

1:32:30

This PER® featured podcast includes a discussion with 3 experts on best practices for integrating opioid-sparing strategies into the treatment paradigm along with updates including the 2025 NOPAIN Act. The panel includes members of the care team including the surgical oncologist and anesthesiologist. This program is designed to help clinicians reco…

1
S13 Ep9: Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM 12:53

2M ago12:53

12:53

In today’s episode, we had the pleasure of speaking with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026 president-elect of ASCO. Dr Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and dire…

1
S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma 54:11

2M ago54:11

54:11

This Oncology PER®Spectives™ podcast examines the recent advancements in the treatment landscape for advanced melanoma. In this activity, experts Yana Najjar, MD; Rahul A. Sheth, MD, FSIR; and Douglas Johnson, MD, MSCI, discuss the challenges of immune checkpoint inhibitor resistance and the practical strategies for overcoming this by using direct …

1
JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC 6:54

2M ago6:54

6:54

JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Thomas Stinchcombe discuss the ASCO 2025 Simultaneous Publication paper "Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Ece Cali: Hello, and welcome to our 2025 ASCO …

1
JCO at ASCO Annual Meeting: Lenvatinib Plus Pembrolizumab and Chemotherapy in Gastric Cancer 6:52

2M ago6:52

6:52

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosu…

1
JCO at ASCO Annual Meeting: TTFields in Locally Advanced Pancreatic Adenocarcinoma 6:24

2M ago6:24

6:24

JCO Editorial Fellow Peter Li and JCO Associate Editor Eileen O'Reilly discuss the ASCO 25 Simultaneous Publication paper "Tumor-Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Transcript The guest on this podcast episode has no disclosures…

1
JCO at ASCO Annual Meeting: Avelumab Plus Cetuximab vs. Avelumab in Advanced cSCC 8:42

2M ago8:42

8:42

JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2025 Simultaneous Publication paper "A Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma (cSCC)." Transcript The guest on this podcast episode has no disclosures…

1
JCO at ASCO Annual Meeting: Use of Low-Value Cancer Treatments in Medicare 8:17

2M ago8:17

8:17

JCO Editorial Fellow Dr. Lauren Shih and JCO Associate Editor Dr. Stephanie Wheeler discuss the ASCO 25 Simultaneous Publication paper "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Lauren Shih: Hello, and welcome to our 2025 ASC…

1
S13 Ep7: Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD 9:09

2M ago9:09

9:09

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveill…

1
JCO Article Insights: Double Hit Myeloma Correlates With Adverse Patient Outcome 15:50

2M ago15:50

15:50

In this JCO Article Insights episode, host Michael Hughes summarizes "Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma" by Kaiser et al, published February 18, 2025, followed by an interview with JCO Associate Editor Suzanne Lentzsch. Transcript Michael Hughes: Welcome to t…

1
S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD 7:48

2M ago7:48

7:48

In today’s episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medi…

1
S13 Ep5: Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD 8:56

2M ago8:56

8:56

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Paul Hanona, MD, to give advice to up-and-coming oncology content creators. Dr Hanona is a content creator under the handle @doctordiscover. In the final part of this 3-part se…

1
S13 Ep4: Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD 8:24

2M ago8:24

8:24

In today’s episode, supported by Camber Pharmaceuticals, we spoke with Kanwarpal S. Kahlon, MD, an associate clinical professor of medicine at the UCLA School of Medicine. In our exclusive interview, Dr Kahlon discussed the significance of the commercial availability of the generic, AB-rated formulations of eltrombopag (Promacta), a bioequivalent m…

1
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD 12:59

2M ago12:59

12:59

In today’s episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our ex…

1
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer 49:30

3M ago49:30

49:30

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with …

1
S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott 24:09

3M ago24:09

24:09

In today’s episode, we spoke with Shubham Pant, MD, MBBS, and Professor Timothy Elliott, about ongoing research with cancer vaccines. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr Elliott is the Kidani Professor of …

1
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2 43:33

3M ago43:33

43:33

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educat…

1
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD 12:54

3M ago12:54

12:54

In today’s episode, supported by SpringWorks Therapeutics, we spoke with Christopher L. Moertel, MD, about the evolution of treatments for neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PN). Dr Moertel is a professor and the Pediatric Neuro-Oncology Fellowship Program director in the Division of Pediatric Hematology/Oncology, a …

1
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation 1:17:00

3M ago1:17:00

1:17:00

This featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Brea…

1
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD 9:43

3M ago9:43

9:43

In today’s episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discuss…

1
Pembrolizumab and Bevacizumab for Melanoma Brain Metastases 23:59

3M ago23:59

23:59

Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down wit…

1
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer 1:04:27

3M ago1:04:27

1:04:27

This expert podcast includes an engaging discussion among 3 experts on fertility care of patients with breast cancer. This program is designed to help clinicians better recognize and take steps to discuss fertility options in premenopausal patients with hormone receptor-positive (HR+) breast cancer to facilitate care for those women who wish to pre…